falsefalse

Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 1

Overview of Current ADCs in Breast Cancer

,

Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Overview of Current ADCs in Breast Cancer
    EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
    EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
    EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
    EP. 5: Navigating SG-related Diarrhea
    EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
    EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
    EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd
    EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
    EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
    EP. 11: Future Perspectives on ADCs in Breast Cancer
    EP. 12: Expert Insights: Investigational ADCs Safety Profiles
    EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

    Video content above is prompted by the following:

    • Can you briefly review which currently available antibody-drug conjugates we have for breast cancer?

    Related Content:

    Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer Video SeriesClinicalOncLive Peer Exchange® Breast Cancer
    Pembrolizumab-Based Regimens Gain Ground in TNBC Management
    CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024
    Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC
    x